PDF(Pubmed)
Abstract：
UNASSIGNED: The use of gentamicin in the treatment of infectious diseases requires frequent monitoring to attain the best treatment outcomes.
UNASSIGNED: This study aimed to evaluate the appropriateness of gentamicin therapeutic drug monitoring (TDM) at a tertiary care hospital in Qatar.
UNASSIGNED: A one-year quantitative retrospective chart review of all gentamicin TDM records was conducted. Evidence-based criteria were applied to evaluate the appropriateness of gentamicin TDM in terms of indication, sampling times, and post-analytical actions.
UNASSIGNED: Out of 59 captured gentamicin TDM records, 58 gentamicin samples were eligible for evaluation. Overall, gentamicin TDM appropriateness was achieved in 50% (n = 29) of the evaluated records. However, 12% (n = 7) of gentamicin drug concentrations were below the assay quantification limits or were not sampled appropriately. Inappropriate post-analytical actions (22.4%, n = 13) and inappropriate sampling times (44.8%, n = 26) were recorded. Most of the gentamicin blood samples (n = 43; 74.2%) were taken appropriately at steady-state. Inappropriate sampling time relative to the last dose was captured in 31% (n = 18) of the cases. Although 27.6% (n = 16) of gentamicin concentrations were non-therapeutic, continuing gentamicin dosing without adjustment was the most frequent post-analytical action (69.8%, n = 37). Gentamicin dose regimen continuations, dose regimen decreases and dose regimen discontinuations were inappropriately applied in 27% (n = 10), 25% (n = 2) and 14% (n = 1) of the times, respectively.
UNASSIGNED: Suboptimal gentamicin TDM practices exist in relation to sampling time and post-analytical actions. Studies exploring setting-specific reasons behind inappropriate TDM practices and methods of its optimisation are needed.
UNASSIGNED: This study aimed to evaluate the appropriateness of gentamicin therapeutic drug monitoring (TDM) at a tertiary care hospital in Qatar.
UNASSIGNED: A one-year quantitative retrospective chart review of all gentamicin TDM records was conducted. Evidence-based criteria were applied to evaluate the appropriateness of gentamicin TDM in terms of indication, sampling times, and post-analytical actions.
UNASSIGNED: Out of 59 captured gentamicin TDM records, 58 gentamicin samples were eligible for evaluation. Overall, gentamicin TDM appropriateness was achieved in 50% (n = 29) of the evaluated records. However, 12% (n = 7) of gentamicin drug concentrations were below the assay quantification limits or were not sampled appropriately. Inappropriate post-analytical actions (22.4%, n = 13) and inappropriate sampling times (44.8%, n = 26) were recorded. Most of the gentamicin blood samples (n = 43; 74.2%) were taken appropriately at steady-state. Inappropriate sampling time relative to the last dose was captured in 31% (n = 18) of the cases. Although 27.6% (n = 16) of gentamicin concentrations were non-therapeutic, continuing gentamicin dosing without adjustment was the most frequent post-analytical action (69.8%, n = 37). Gentamicin dose regimen continuations, dose regimen decreases and dose regimen discontinuations were inappropriately applied in 27% (n = 10), 25% (n = 2) and 14% (n = 1) of the times, respectively.
UNASSIGNED: Suboptimal gentamicin TDM practices exist in relation to sampling time and post-analytical actions. Studies exploring setting-specific reasons behind inappropriate TDM practices and methods of its optimisation are needed.
摘要：
■在传染病的治疗中使用庆大霉素需要经常监测以获得最佳的治疗结果。
■本研究旨在评估庆大霉素治疗药物监测（TDM）在卡塔尔一家三级保健医院的适当性。
■对所有庆大霉素TDM记录进行了为期一年的定量回顾性图表审查。采用循证标准评估庆大霉素TDM在适应症方面的适当性。采样次数,和分析后的行动。
■在59条捕获的庆大霉素TDM记录中，58个庆大霉素样品符合评估条件。总的来说,在50％（n=29）的评估记录中实现了庆大霉素TDM适当性。然而,12%(n=7)的庆大霉素药物浓度低于测定定量限或未适当取样。不适当的分析后行动(22.4%，n=13)和不适当的采样时间(44.8%，记录n=26）。大多数庆大霉素血样(n=43;74.2%)是在稳态下适当采集的。在31%(n=18)的病例中捕获了相对于最后剂量的不适当的采样时间。虽然27.6%(n=16)的庆大霉素浓度是非治疗性的，继续给予庆大霉素而不调整是最常见的分析后行动(69.8%，n=37）。庆大霉素剂量方案延续，剂量方案减少和剂量方案终止不适当地应用于27%(n=10)，25%(n=2)和14%(n=1)的次数，分别。
■庆大霉素TDM实践与采样时间和分析后行动有关。需要研究探索不适当的TDM实践背后的特定设置原因及其优化方法。
■本研究旨在评估庆大霉素治疗药物监测（TDM）在卡塔尔一家三级保健医院的适当性。
■对所有庆大霉素TDM记录进行了为期一年的定量回顾性图表审查。采用循证标准评估庆大霉素TDM在适应症方面的适当性。采样次数,和分析后的行动。
■在59条捕获的庆大霉素TDM记录中，58个庆大霉素样品符合评估条件。总的来说,在50％（n=29）的评估记录中实现了庆大霉素TDM适当性。然而,12%(n=7)的庆大霉素药物浓度低于测定定量限或未适当取样。不适当的分析后行动(22.4%，n=13)和不适当的采样时间(44.8%，记录n=26）。大多数庆大霉素血样(n=43;74.2%)是在稳态下适当采集的。在31%(n=18)的病例中捕获了相对于最后剂量的不适当的采样时间。虽然27.6%(n=16)的庆大霉素浓度是非治疗性的，继续给予庆大霉素而不调整是最常见的分析后行动(69.8%，n=37）。庆大霉素剂量方案延续，剂量方案减少和剂量方案终止不适当地应用于27%(n=10)，25%(n=2)和14%(n=1)的次数，分别。
■庆大霉素TDM实践与采样时间和分析后行动有关。需要研究探索不适当的TDM实践背后的特定设置原因及其优化方法。
